| Bioactivity | CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC50s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis[1][2][3]. |
| Invitro | CMC2.24 (0-60 μM; 24 hours) inhibits pancreatic cancer growth in vitro[1].CMC2.24 reduces STAT3Ser727 phosphorylation levels, induces mitochondrial reactive oxygen species and mitochondrial cell death in pancreatic cancer cells. CMC2.24 induces mitochondrial reactive oxygen species and intrinsic apoptosis[1]. Cell Viability Assay[1] Cell Line: |
| Name | CMC2.24 |
| CAS | 1255639-43-0 |
| Formula | C26H21NO5 |
| Molar Mass | 427.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
CMC2.24
CAS: 1255639-43-0 F: C26H21NO5 W: 427.45
CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibit
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.